535 related articles for article (PubMed ID: 30771238)
1. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
2. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
4. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
5. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
8. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
9. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
van Vollenhoven RF; Navarra SV; Levy RA; Thomas M; Heath A; Lustine T; Adamkovic A; Fettiplace J; Wang ML; Ji B; Roth D
Rheumatology (Oxford); 2020 Feb; 59(2):281-291. PubMed ID: 31302695
[TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
14. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
Tanaka Y; Bae SC; Bass D; Curtis P; Chu M; DeRose K; Ji B; Kurrasch R; Lowe J; Meizlik P; Roth DA
RMD Open; 2021 Jul; 7(2):. PubMed ID: 34215703
[TBL] [Abstract][Full Text] [Related]
15. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
16. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
17. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
[TBL] [Abstract][Full Text] [Related]
18. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
Tanaka Y; Curtis P; DeRose K; Kurrasch R; Kinoshita K; Tanaka R; Yamazaki Y; Roth DA
Mod Rheumatol; 2023 Jan; 33(1):122-133. PubMed ID: 34915574
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]